1
|
Sinha D, Nagy-Mehesz A, Simionescu D, Mayer JE, Vyavahare N. Pentagalloyl glucose-stabilized decellularized bovine jugular vein valved conduits as pulmonary conduit replacement. Acta Biomater 2023; 170:97-110. [PMID: 37619898 PMCID: PMC10592392 DOI: 10.1016/j.actbio.2023.08.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 08/17/2023] [Accepted: 08/17/2023] [Indexed: 08/26/2023]
Abstract
Congenital heart diseases (CHD) are one of the most frequently diagnosed congenital disorders, affecting approximately 40,000 live births annually in the United States. Out of the new patients diagnosed with CHD yearly, an estimated 2,500 patients require a substitute, non-native conduit artery to replace structures congenitally absent or hypoplastic. Devices used for conduit replacement encounter limitations exhibiting varying degrees of stiffness, calcification, susceptibility to infection, thrombosis, and a lack of implant growth capacity. Here, we report the functionality of pentagalloyl glucose (PGG) stabilized decellularized valved bovine jugular vein conduit (PGG-DBJVC). The PGG-DBJVC tissues demonstrated mechanical properties comparable to native and glutaraldehyde fixed tissues, while exhibiting resistance to both collagenase and elastase enzymatic degradation. Subcutaneous implantation of tissues established their biocompatibility and resistance to calcification, while implantation in sheep in the pulmonary position demonstrated adequate implant functionality, and repopulation of host cells, without excessive inflammation. In conclusion, this PGG-DBJVC device could be a favorable replacement option for pediatric patients, reducing the need for reoperations required with current devices. STATEMENT OF SIGNIFICANCE: Congenital Heart Disease (CHD) is a common congenital disorder affecting many newborns in the United States each year. The use of substitute conduit arteries is necessary for some patients with CHD who have missing or underdeveloped structures. Current conduit replacement devices have limitations, including stiffness, susceptibility to infection and thrombosis, and lack of implant growth capacity. Pentagalloyl glucose-stabilized bovine jugular vein valved tissue (PGG-DBJVC) offers a promising solution as it is resistant to calcification, and biocompatible. When implanted in rats and as pulmonary conduit replacement in sheep, the PGG-DBJVC demonstrated cellular infiltration without excessive inflammation, which could lead to remodeling and integration with host tissue and eliminate the need for replacement as the child grows.
Collapse
Affiliation(s)
- Dipasha Sinha
- Department of Bioengineering, College of Engineering, Computing and Applied Sciences, Clemson University, Clemson, South Carolina 29634, USA
| | - Agnes Nagy-Mehesz
- Department of Bioengineering, College of Engineering, Computing and Applied Sciences, Clemson University, Clemson, South Carolina 29634, USA
| | - Dan Simionescu
- Department of Bioengineering, College of Engineering, Computing and Applied Sciences, Clemson University, Clemson, South Carolina 29634, USA
| | - John E Mayer
- Department of Cardiac Surgery, Boston Children's Hospital, Boston, Massachusetts; Department of Surgery, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Naren Vyavahare
- Department of Bioengineering, College of Engineering, Computing and Applied Sciences, Clemson University, Clemson, South Carolina 29634, USA.
| |
Collapse
|
2
|
Cheng SWK, Eagleton M, Echeverri S, Munoz JG, Holden AH, Hill AA, Krievins D, Ramaiah V. A pilot study to evaluate a novel localized treatment to stabilize small- to medium-sized infrarenal abdominal aortic aneurysms. J Vasc Surg 2023; 78:929-935.e1. [PMID: 37330148 DOI: 10.1016/j.jvs.2023.05.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 05/23/2023] [Accepted: 05/25/2023] [Indexed: 06/19/2023]
Abstract
OBJECTIVE There is no proven therapy to reduce growth rates of small- to medium-sized abdominal aortic aneurysms (AAAs). Ex vivo and animal studies have demonstrated that a novel stabilizing agent, 1,2,3,4,6-pentagalloyl glucose (PGG), delivered locally to the aneurysm sac, can bind to elastin and collagen to re-establish strength and resist enzymatic degradation. We aimed to demonstrate that a one-time administration of PGG solution to the aneurysm wall is safe and potentially effective to slow the growth of small- to medium-sized AAAs. METHODS Patients with small- to medium-sized infrarenal AAAs (maximum diameter <5.5 cm) were recruited. Via transfemoral access, a 14F or 16F dual-balloon delivery catheter was introduced into the aneurysm sac. A single, 3-minute, localized endoluminal infusion of PGG was delivered via a 'weeping' balloon to the aneurysm wall. Independent core laboratory measurements of maximum aneurysm sac diameter and sac volume measurements based on computed tomography angiography (CTA) were used for assessments at 1, 6, 12, 24, and 36 months. The primary endpoints were technical success and safety (major adverse events at 30 days). The secondary endpoint was growth stabilization, defined as freedom from aneurysm sac enlargement (diameter increase >5 mm per year or volume increase of >10% per year). RESULTS Twenty patients (19 male) were enrolled at five centers from May 2019 to June 2022 (mean age, 67.8 years; range, 50-87 years). All procedures were technically successful. The safety profile was consistent with standard interventional procedures. Four patients demonstrated transient elevations of liver enzymes levels that returned to normal by 30 days with no clinical symptoms. Through November 2022, follow-up CTA data is available on the first 11 patients. The average changes in maximum aneurysm diameter from baseline to 6, 12, 24, and 36 months were 0.2 mm, 1.1 mm, 1.2 mm, and 0.8 mm, respectively, and the average changes in volume were 2.0%, 9.6%, 18.1%, and 11.6%, respectively. At 12 months, none of the aneurysms showed growth >5.0 mm, and three had volume growth >10%. CONCLUSIONS The early results of this first-in-human, small cohort study demonstrated that a single, localized PGG administration to patients with small- to medium-sized infrarenal AAAs is safe. Longer term follow-up on all 20 treated patients is needed to better assess the potential impact on aneurysm growth.
Collapse
Affiliation(s)
- Stephen W K Cheng
- Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
| | | | | | | | - Andrew H Holden
- Associate Professor Radiology, Director of Northern Region Interventional Radiology Service, Auckland University School of Medicine, Auckland City Hospital, Auckland, New Zealand
| | | | - Dainis Krievins
- Pauls Stradins Clinical University Hospital, University of Latvia Faculty of Medicine, Riga, Latvia
| | | |
Collapse
|
3
|
The matrix reloaded – addressing structural integrity of the aortic wall in aneurysmal disease. BIOMATERIALS AND BIOSYSTEMS 2023; 9:100072. [PMID: 36967726 PMCID: PMC10036219 DOI: 10.1016/j.bbiosy.2023.100072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2022] [Revised: 01/03/2023] [Accepted: 01/14/2023] [Indexed: 01/19/2023] Open
Abstract
Thoracic aortic aneurysms and dissections (TAADs) involve dilation of the aortic wall that can lead to tearing or rupture. Progressive extracellular matrix (ECM) degradation is common in TAAD, regardless of the underlying cause. TAAD treatments typically target cellular signaling pathways, rather than the ECM itself, due to the complex assembly process and long half-life of ECM proteins. Compounds that stabilize the ECM are proposed as an alternative TAAD therapy that addresses the underlying cause of aortic wall failure, namely compromised structural integrity. Compounds are discussed that revisit historical approaches to maintain and preserve structural integrity of biological tissues.
Collapse
|
4
|
Mechanistic insight into lysyl oxidase in vascular remodeling and angiogenesis. Genes Dis 2022. [DOI: 10.1016/j.gendis.2022.05.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
5
|
Guang Y, Cocciolone AJ, Crandall CL, Johnston BB, Setton LA, Wagenseil JE. A multiphasic model for determination of water and solute transport across the arterial wall: effects of elastic fiber defects. ARCHIVE OF APPLIED MECHANICS = INGENIEUR-ARCHIV 2022; 92:447-459. [PMID: 35386426 PMCID: PMC8983017 DOI: 10.1007/s00419-021-01985-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
Transport of solute across the arterial wall is a process driven by both convection and diffusion. In disease, the elastic fibers in the arterial wall are disrupted and lead to altered fluid and mass transport kinetics. A computational mixture model was used to numerically match previously published data of fluid and solute permeation experiments in groups of mouse arteries with genetic (knockout of fibulin-5) or chemical (treatment with elastase) disruption of elastic fibers. A biphasic model of fluid permeation indicated the governing property to be the hydraulic permeability, which was estimated to be 1.52×10-9, 1.01×10-8, and 1.07×10-8 mm4/μN.s for control, knockout, and elastase groups, respectively. A multiphasic model incorporating solute transport was used to estimate effective diffusivities that were dependent on molecular weight, consistent with expected transport behaviors in multiphasic biological tissues. The effective diffusivity for the 4 kDA FITC-dextran solute, but not the 70 or 150 kDa FITC-dextran solutes, was dependent on elastic fiber structure, with increasing values from control to knockout to elastase groups, suggesting that elastic fiber disruption affects transport of lower molecular weight solutes. The model used here sets the groundwork for future work investigating transport through the arterial wall.
Collapse
Affiliation(s)
- Young Guang
- Department of Biomedical Engineering, Washington University, St. Louis, MO, USA
| | - Austin J Cocciolone
- Department of Biomedical Engineering, Washington University, St. Louis, MO, USA
| | - Christie L Crandall
- Department of Mechanical Engineering and Materials Science, Washington University, St. Louis, MO, USA
| | - Benjamin B Johnston
- Department of Biomedical Engineering, Washington University, St. Louis, MO, USA
| | - Lori A Setton
- Department of Biomedical Engineering, Washington University, St. Louis, MO, USA
| | - Jessica E Wagenseil
- Department of Mechanical Engineering and Materials Science, Washington University, St. Louis, MO, USA
| |
Collapse
|
6
|
Golledge J, Thanigaimani S, Phie J. A Systematic Review and Meta-Analysis of the Effect of Pentagalloyl Glucose Administration on Aortic Expansion in Animal Models. Biomedicines 2021; 9:biomedicines9101442. [PMID: 34680560 PMCID: PMC8533208 DOI: 10.3390/biomedicines9101442] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 10/08/2021] [Accepted: 10/08/2021] [Indexed: 12/30/2022] Open
Abstract
Background: The aim of this systematic review was to pool evidence from studies testing if pentagalloyl glucose (PGG) limited aortic expansion in animal models of abdominal aortic aneurysm (AAA). Methods: The review was conducted according to the PRISMA guidelines and registered with PROSPERO. The primary outcome was aortic expansion assessed by direct measurement. Secondary outcomes included aortic expansion measured by ultrasound and aortic diameter at study completion. Sub analyses examined the effect of PGG delivery in specific forms (nanoparticles, periadventitial or intraluminal), and at different times (from the start of AAA induction or when AAA was established), and tested in different animals (pigs, rats and mice) and AAA models (calcium chloride, periadventitial, intraluminal elastase or angiotensin II). Meta-analyses were performed using Mantel-Haenszel’s methods with random effect models and reported as mean difference (MD) and 95% confidence intervals (CIs). Risk of bias was assessed with a customized tool. Results: Eleven studies reported in eight publications involving 214 animals were included. PGG significantly reduced aortic expansion measured by direct observation (MD: −66.35%; 95% CI: −108.44, −24.27; p = 0.002) but not ultrasound (MD: −32.91%; 95% CI: −75.16, 9.33; p = 0.127). PGG delivered intravenously within nanoparticles significantly reduced aortic expansion, measured by both direct observation (MD: −116.41%; 95% CI: −132.20, −100.62; p < 0.001) and ultrasound (MD: −98.40%; 95% CI: −113.99, −82.81; p < 0.001). In studies measuring aortic expansion by direct observation, PGG administered topically to the adventitia of the aorta (MD: −28.41%; 95% CI −46.57, −10.25; p = 0.002), studied in rats (MD: −56.61%; 95% CI: −101.76, −11.46; p = 0.014), within the calcium chloride model (MD: −56.61%; 95% CI: −101.76, −11.46; p = 0.014) and tested in established AAAs (MD: −90.36; 95% CI: −135.82, −44.89; p < 0.001), significantly reduced aortic expansion. The findings of other analyses were not significant. The risk of bias of all studies was high. Conclusion: There is inconsistent low-quality evidence that PGG inhibits aortic expansion in animal models.
Collapse
Affiliation(s)
- Jonathan Golledge
- Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD 4810, Australia; (S.T.); (J.P.)
- The Department of Vascular and Endovascular Surgery, The Townsville Hospital, Townsville, QLD 4810, Australia
- The Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, QLD 4810, Australia
- Correspondence: ; Tel.: +61-7-4796-1417; Fax: +61-7-4796-1401
| | - Shivshankar Thanigaimani
- Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD 4810, Australia; (S.T.); (J.P.)
- The Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, QLD 4810, Australia
| | - James Phie
- Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD 4810, Australia; (S.T.); (J.P.)
- The Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, QLD 4810, Australia
| |
Collapse
|
7
|
Wang X, Parasaram V, Dhital S, Nosoudi N, Hasanain S, Lane BA, Lessner SM, Eberth JF, Vyavahare NR. Systemic delivery of targeted nanotherapeutic reverses angiotensin II-induced abdominal aortic aneurysms in mice. Sci Rep 2021; 11:8584. [PMID: 33883612 PMCID: PMC8060294 DOI: 10.1038/s41598-021-88017-w] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2020] [Accepted: 03/25/2021] [Indexed: 01/04/2023] Open
Abstract
Abdominal aortic aneurysm (AAA) disease causes dilation of the aorta, leading to aortic rupture and death if not treated early. It is the 14th leading cause of death in the U.S. and 10th leading cause of death in men over age 55, affecting thousands of patients. Despite the prevalence of AAA, no safe and efficient pharmacotherapies exist for patients. The deterioration of the elastic lamina in the aneurysmal wall is a consistent feature of AAAs, making it an ideal target for delivering drugs to the AAA site. In this research, we conjugated nanoparticles with an elastin antibody that only targets degraded elastin while sparing healthy elastin. After induction of aneurysm by 4-week infusion of angiotensin II (Ang II), two biweekly intravenous injections of pentagalloyl glucose (PGG)-loaded nanoparticles conjugated with elastin antibody delivered the drug to the aneurysm site. We show that targeted delivery of PGG could reverse the aortic dilation, ameliorate the inflammation, restore the elastic lamina, and improve the mechanical properties of the aorta at the AAA site. Therefore, simple iv therapy of PGG loaded nanoparticles can be an effective treatment option for early to middle stage aneurysms to reverse disease progression and return the aorta to normal homeostasis.
Collapse
Affiliation(s)
- Xiaoying Wang
- Department of Bioengineering, Clemson University, 501 Rhodes Engineering Research Center, Clemson, SC, 29634, USA
| | - Vaideesh Parasaram
- Department of Bioengineering, Clemson University, 501 Rhodes Engineering Research Center, Clemson, SC, 29634, USA
| | - Saphala Dhital
- Department of Bioengineering, Clemson University, 501 Rhodes Engineering Research Center, Clemson, SC, 29634, USA
| | - Nasim Nosoudi
- Department of Bioengineering, Clemson University, 501 Rhodes Engineering Research Center, Clemson, SC, 29634, USA.,Biomedical Engineering, College of Engineering & Computer Sciences, Marshall University, Huntington, WV, USA
| | - Shahd Hasanain
- Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, USA
| | - Brooks A Lane
- Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, USA
| | - Susan M Lessner
- Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, USA
| | - John F Eberth
- Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, USA
| | - Naren R Vyavahare
- Department of Bioengineering, Clemson University, 501 Rhodes Engineering Research Center, Clemson, SC, 29634, USA.
| |
Collapse
|
8
|
Anderson JL, Niedert EE, Patnaik SS, Tang R, Holloway RL, Osteguin V, Finol EA, Goergen CJ. Animal Model Dependent Response to Pentagalloyl Glucose in Murine Abdominal Aortic Injury. J Clin Med 2021; 10:E219. [PMID: 33435461 PMCID: PMC7827576 DOI: 10.3390/jcm10020219] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 12/23/2020] [Accepted: 12/28/2020] [Indexed: 12/21/2022] Open
Abstract
Abdominal aortic aneurysms (AAAs) are a local dilation of the aorta and are associated with significant mortality due to rupture and treatment complications. There is a need for less invasive treatments to prevent aneurysm growth and rupture. In this study, we used two experimental murine models to evaluate the potential of pentagalloyl glucose (PGG), which is a polyphenolic tannin that binds to and crosslinks elastin and collagen, to preserve aortic compliance. Animals underwent surgical aortic injury and received 0.3% PGG or saline treatment on the adventitial surface of the infrarenal aorta. Seventeen mice underwent topical elastase injury, and 14 mice underwent topical calcium chloride injury. We collected high-frequency ultrasound images before surgery and at 3-4 timepoints after. There was no difference in the in vivo effective maximum diameter due to PGG treatment for either model. However, the CaCl2 model had significantly higher Green-Lagrange circumferential cyclic strain in PGG-treated animals (p < 0.05). While ex vivo pressure-inflation testing showed no difference between groups in either model, histology revealed reduced calcium deposits in the PGG treatment group with the CaCl2 model. These findings highlight the continued need for improved understanding of PGG's effects on the extracellular matrix and suggest that PGG may reduce arterial calcium accumulation.
Collapse
Affiliation(s)
- Jennifer L. Anderson
- Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA; (J.L.A.); (E.E.N.); (R.T.); (R.L.H.)
| | - Elizabeth E. Niedert
- Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA; (J.L.A.); (E.E.N.); (R.T.); (R.L.H.)
| | - Sourav S. Patnaik
- Department of Mechanical Engineering, University of Texas, San Antonio, TX 78249, USA; (S.S.P.); (V.O.); (E.A.F.)
| | - Renxiang Tang
- Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA; (J.L.A.); (E.E.N.); (R.T.); (R.L.H.)
| | - Riley L. Holloway
- Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA; (J.L.A.); (E.E.N.); (R.T.); (R.L.H.)
| | - Vangelina Osteguin
- Department of Mechanical Engineering, University of Texas, San Antonio, TX 78249, USA; (S.S.P.); (V.O.); (E.A.F.)
| | - Ender A. Finol
- Department of Mechanical Engineering, University of Texas, San Antonio, TX 78249, USA; (S.S.P.); (V.O.); (E.A.F.)
| | - Craig J. Goergen
- Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA; (J.L.A.); (E.E.N.); (R.T.); (R.L.H.)
| |
Collapse
|